Equillium Inc

NASDAQ:EQ   10:22:04 AM EDT
5.90
+0.11 (+1.90%)
Products, Other Pre-Announcement

Equillium Announces Plans To Initiate Phase 3 Pivotal Study Of Itolizumab In First-Line Treatment Of Acute Graft-Versus-Host Disease Following End-Of-Phase 1 Meeting With The FDA

Published: 07/12/2021 20:15 GMT
Equillium Inc (EQ) - Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-versus-host Disease Following End-of-phase 1 Meeting With the FDA.
Equillium Inc - on Track to Initiate Study in Q4 2021.
Equillium Inc - Finalizing Details of Phase 3 Protocol Based on Feedback and Guidance From FDA.